Known drug-drug interactions (DDIs) are responsible for 13 percent of adverse drug events and 4.8 percent of hospital admissions in older adults. Even these high figures may understate the true impact of DDIs because they include only the effects of known interactions. Many clinically important DDIs take years to discover. Given the widespread and growing use of multiple medications by persons with diabetes, there is tremendous potential for DDIs to occur in this population. Of the ten most commonly used second-line antidiabetic agents, five are insulin secretagogues, which, based on known metabolic pathways, may interact with many commonly- prescribed medications. DDIs involving insulin secretagogues can cause serious hypoglycemia, which can be immediately life-threatening and have cause long-term consequences. The broad objective of this project is to produce clinically-actionable knowledge about which drugs interact with insulin secretagogues to cause serious hypoglycemia, as well as the time-course of such interactions and the subgroups most susceptible to these DDIs. We will achieve this objective by taking a translational science approach to DDIs in which we 1) perform high-throughput simulation of potential DDIs based on pharmacologic knowledge; 2) perform high-throughput screening of healthcare data; and then 3) confirm (or refute) and elucidate selected high-probability DDIs in an independent population by conducting in-depth pharmacoepidemiologic studies. This project will produce clinically-actionable knowledge about which drugs interact with secretagogues to cause severe hypoglycemia, and generalizable biological knowledge about the drugs and pathways involved in these interactions.

Public Health Relevance

Drug-drug interactions (DDIs) are a major clinical and public health burden. Given that most individuals with type 2 diabetes mellitus take five or more medications, they are at high risk for clinically significant DDIs. Insulin secretagogues are used by many patients with diabetes, and have a high potential to cause serious hypoglycemia, especially in the setting of DDIs. This study will produce clinically-actionable knowledge about which drugs interact with insulin secretagogues to cause serious hypoglycemia, as well as the time-course of such interactions and the subgroups most susceptible to these DDIs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK102694-02
Application #
8891420
Study Section
Health Services Organization and Delivery Study Section (HSOD)
Program Officer
Bremer, Andrew
Project Start
2014-07-15
Project End
2018-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
2
Fiscal Year
2015
Total Cost
$589,186
Indirect Cost
$176,936
Name
University of Pennsylvania
Department
Biostatistics & Other Math Sci
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ertefaie, Ashkan; Small, Dylan S; Ji, Xinyao et al. (2018) Statistical Power for Trend-in-trend Design. Epidemiology 29:e21-e23
Wang, Xueying; Zhang, Pengyue; Chiang, Chien-Wei et al. (2018) Mixture drug-count response model for the high-dimensional drug combinatory effect on myopathy. Stat Med 37:673-686
Alam, Khondoker; Crowe, Alexandra; Wang, Xueying et al. (2018) Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci 19:
Leonard, Charles E; Brensinger, Colleen M; Aquilante, Christina L et al. (2018) Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. Diabetes Care 41:713-722
Leonard, Charles E; Han, Xu; Brensinger, Colleen M et al. (2018) Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiol Drug Saf 27:9-18
Leonard, Charles E; Hennessy, Sean; Han, Xu et al. (2017) Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends Endocrinol Metab 28:561-586
Leonard, Charles E; Brensinger, Colleen M; Bilker, Warren B et al. (2017) Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. Int J Cardiol 228:761-770
Ji, Xinyao; Small, Dylan S; Leonard, Charles E et al. (2017) The Trend-in-trend Research Design for Causal Inference. Epidemiology 28:529-536
Han, Xu; Chiang, ChienWei; Leonard, Charles E et al. (2017) Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues. Epidemiology 28:459-468
Leonard, Charles E; Brensinger, Colleen M; Nam, Young Hee et al. (2017) The quality of Medicaid and Medicare data obtained from CMS and its contractors: implications for pharmacoepidemiology. BMC Health Serv Res 17:304

Showing the most recent 10 out of 31 publications